NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » MDS Pharma Services back to previous page show list

MDS Pharma Services

address: Suite 505, Prime Tower,
No. 22 Chao Wai Street,
Chao Yang District,
Beijing 100020, China
contact: China
Suite 505, Prime Tower,
No. 22 Chao Wai Street,
Chao Yang District,
Beijing 100020, China
Tel: +86-10-6588-9009
Fax: +86-10-6588-9010
Services: Global Clinical Development

6 Tian Tan Xi
key person: David Spaight
President
MDS Pharma Services

Riaz Bandali
Vice President and General Manager
Global Early Clinical Research

Robert Béland
Group Vice President
Discovery and Preclinica

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 4000

active in China: NO
partner in China: MDS(Beijing)Drug Group Ltd.

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 

Overview

It continues with a global infrastructure of facilities strategically located around the world, linked to a robust, integrated IT network with superior reliability. MDS Pharma Services applies its advanced scientific and technological expertise throughout the drug discovery and development process – from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases II-IV), central lab and centralized cardiac services.

It all comes together via an interconnected network of dedicated teams focused on managing your projects through the drug development continuum. More importantly, our capability and expertise to both customize and execute your research and development programs further accelerate your drug's development.
 
MDS Pharma Services has created a Drug Development Programs service that tailors our program management approach to meet the specific needs of each client, providing full program and scientific consulting, project management and program facilitation. Our Small Molecule Development Program is just one example of the versatility and scope available through Development and Regulatory Services.
 
From the start, MDS Pharma Services works with you as an integrated team. Our efforts are led by a senior level scientist/manager experienced in drug development who serves as the program leader. All aspects, including contracting, conduct and follow-up, are addressed through Development and Regulatory Services.
 
MDS in China
 
The MDS Beijing carries out the buiness mainly in the field of global clinical development (Phase Ⅱ-).Six company-owned central lab facilities strategically located around the globe.Central lab in Beijing which had approved CAP (College of American Pathologists) in 2005.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.